期刊文献+

hs-CRP、GMP-140和cTnI联检在CHD患者的应用 被引量:2

Clinical Application of Combined Detection of Serum hs-CRP,GMP-140 and cTnI in Patients with Coronary Heart Diseases
下载PDF
导出
摘要 目的:探讨了超敏C反应蛋白(hs-CRP)、颗粒膜蛋白-140(GMP-140)和肌钙蛋白T(cTnI)水平的变化与冠心病(CHD)患者的关系及临床价值。方法:应用放射免疫分析、酶联法和免疫比浊法对91例CHD患者进行了血清hs-CRP、GMP-140和cTnI测定,其中稳定型心绞痛(SAP)42例,不稳定型心绞痛(UAP)34例,急性心梗死(AMI)15例,并与35名正常人作比较。结果:CHD患者血清hs-CRP、GMP-140和cTnI水平均非常显著地高于正常人组(P<0.01),急性AMI组和UAP组均高于SAP组(P<0.05),且血清hs-CRP水平与GMP-140、cTnI水平呈正相关(r=0.6214、0.6023,P<0.01)。结论:检测CHD患者血清hs-CRP、GMP-140和cTnI水平的变化及CHD的发生和发展以及疗效和预后观察具有重要的临床意义。 Objective To explore the clinical significance of changes of serum hs-CRP,GMP-140 and cTnI levels in patients with coronary heart diseases.Methods Serum GMP-140 (with RIA) ,cTnI (with ELISA) and hs-CRP (with immunoturbidity method) levels were determined in 91 patients with coronary heart diseases (42 SAP,34UAP,15AMI) and 35 controls.Results Serum hs-CRP,GMP-140,cTnI levels in patients with coronary heart diseases were significantly higher than those in controls (P〈 0.01) .Among the patients with of coronary heart diseases,the magnitude of changes of the levels of serum hs-CRP,GMP-140 and cTnI levels in AMI and UAP groups were significantly larger than those in SAP group (P〈 0.05) .Serum hs-CRP levels were positively correlated with serum GMP-140 and cTnI levels (r = 0.6214,0.6023,P〈 0.01) .Conclusion Serum hs-CRP,GMP140 and cTnI levels were closely related to the diseases process of coronary heart diseases and were of great clinical importance for assessment of the disease and outcome prediction.
出处 《放射免疫学杂志》 CAS 2010年第5期498-499,共2页 Journal of Radioimmanology
关键词 冠心病 超敏C反应蛋白 颗粒膜蛋白-140 肌钙蛋白T 稳定型心绞痛 不稳定型心绞痛 急性心肌梗死 coronary heart diseases (CHD) high-sensitive C-reactive protein (hs-CRP) granular membranous protein-140 (GMP-140) troponin I (cTnI) stable angina pectoris (SAP) unstable angina pectoris (UAP) acute myocardial infarction (AMI)
  • 相关文献

参考文献9

二级参考文献35

  • 1杨振修.钩状效应与免疫学检验[J].上海医学检验杂志,1994,9(2):111-112. 被引量:21
  • 2杨振修 唐卫国.免疫学诊断试剂.医学检验诊断试剂的制备与应用[M].上海科学技术出版社,1996.99-101,114-119,129-137.
  • 3Hopkins PN,Williams RR. A survey of 246 suggested coronary risk factors[J]. Atherosclerosis, 1981,40:1-52.
  • 4EUROASPIRE:a Europan Society of Cardiology survery of secondary prevention of coronary heart disease: principal results[J]. Eur Heart J, 1997,18:1569-1582.
  • 5Ross R. Atheroslerosis-an inflammatory disease[J]. N Engl J Med, 1999,340:115-126.
  • 6Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages:implications for atherosclerosis [ J]. Circulation, 2001,103 :1194-1197.
  • 7Nakagomi A, Freedman SB, Geczy CL. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex,and hormone replacement treatment [J]. Circulation, 2000,101:1785-1791.
  • 8Penn MS, Topol EJ. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling[J]. Cir Res, 2001,89:1-2.
  • 9Yasojima K,Schwab C, McGeer EG, et al. Generation of C-Reactive protein and complement components in atheroscle-rotic plaques[J]. Am J Pathol,2001,158 : 1039-1051.
  • 10Tomai F,Crea F,Gaspardone A, et al. Unstable angina and elevated C-reactive protein levels predict enhanced vasore-activity of the culprit lesion [J]. Circulation, 2001, 104 :1471-1476.

共引文献425

同被引文献17

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部